You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Details for Patent: 7,381,724


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,381,724
Title:Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same
Abstract:Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-- dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.
Inventor(s): Cotrel; Claude (Paris, FR), Roussel; Gerard (Soisy sur Seine, FR)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:11/416,570
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 7,381,724

Introduction

United States Patent 7,381,724, hereafter referred to as the '724 patent, is a significant document in the patent landscape, particularly in the field it pertains to. To analyze its scope and claims, we need to delve into several key aspects, including the patent's background, its claims, the legal and procedural context, and the broader implications within the patent landscape.

Background of the Patent

The '724 patent is part of a larger family of patents that often arise from continuations-in-part or continuations of earlier patents. Understanding the family tree of patents is crucial because it can affect the patent's term, scope, and potential issues like obviousness-type double patenting (ODP)[1].

Claims of the Patent

The claims of a patent are its most critical component, as they define the scope of the invention. Here are some key points to consider:

Independent and Dependent Claims

  • Independent claims stand alone and define the invention without reference to other claims. They are typically broader and more significant.
  • Dependent claims, on the other hand, refer back to and further limit the independent claims, often adding specific details or features[3].

Claim Length and Count

Research has shown that the length and count of independent claims can be metrics for measuring patent scope. Generally, narrower claims with shorter lengths and fewer counts are associated with a higher probability of grant and a shorter examination process[3].

Specificity and Clarity

The clarity and specificity of claims are vital. Broader claims can lead to issues of patent quality, such as decreased clarity and questionable validity, which can diminish innovation incentives due to increased licensing and litigation costs[3].

Legal and Procedural Context

Obviousness-Type Double Patenting (ODP)

ODP is a critical issue that can arise when multiple patents from the same family are granted. The '724 patent, if part of a family with other patents claiming priority from the same application, must undergo an ODP analysis to prevent an inventor from securing a second, later-expiring patent for the same invention[1].

Patent Term Adjustment (PTA)

The '724 patent, like others in its family, may have been granted PTA for USPTO delays during prosecution. However, PTA does not extend the patent term past the date of a terminal disclaimer, which is often used to overcome ODP rejections[1].

Broader Implications in the Patent Landscape

Patent Scope and Quality

The debate over patent quality is ongoing, with concerns about the breadth and clarity of patents. The '724 patent's claims should be evaluated in this context to ensure they do not contribute to the perceived decrease in patent quality. Metrics such as independent claim length and count can help in this assessment[3].

AI and Patent Eligibility

While the '724 patent may not be directly related to AI, the recent USPTO guidance on AI patent eligibility is relevant for understanding how to draft and evaluate patent claims. The focus on integrating judicial exceptions into practical applications and demonstrating real-world benefits is crucial for patent eligibility, a principle that can be applied broadly across various technologies[4].

Practical Applications and Real-World Benefits

To ensure the '724 patent's claims are patent-eligible, it is essential to highlight their practical applications and real-world benefits. This involves showing how the claimed invention solves specific problems or improves technology in a tangible way, rather than merely involving abstract ideas or routine data processing steps[4].

Stakeholder Input and Public Policy

The design and implementation of patent policies, including those affecting the '724 patent, often involve extensive stakeholder input. For example, the Administrative Conference of the United States (ACUS) has conducted studies on issues like the feasibility of a small claims patent court, which can impact how patents are enforced and litigated[2].

Key Takeaways

  • Claims Analysis: The scope of the '724 patent is defined by its claims, which must be specific, clear, and narrowly tailored to avoid issues of patent quality and ODP.
  • Legal Context: The patent must comply with legal requirements such as ODP analysis and PTA rules to ensure its validity and term.
  • Broader Implications: The patent's claims should align with broader patent landscape issues, including the need for practical applications and real-world benefits.
  • Stakeholder Input: Public policy and stakeholder input play a crucial role in shaping the patent landscape and ensuring that patents like the '724 patent serve to promote innovation.

FAQs

Q: What is the significance of independent claim length and count in patent scope analysis?

  • Independent claim length and count are metrics used to measure patent scope. Narrower claims with shorter lengths and fewer counts are associated with a higher probability of grant and a shorter examination process[3].

Q: How does Obviousness-Type Double Patenting (ODP) affect patents like the '724 patent?

  • ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of PTA. This requires an ODP analysis to ensure the patent's validity[1].

Q: What is the role of Patent Term Adjustment (PTA) in the context of the '724 patent?

  • PTA is granted for USPTO delays during prosecution but does not extend the patent term past the date of a terminal disclaimer, which is often used to overcome ODP rejections[1].

Q: How does the recent USPTO guidance on AI patent eligibility impact the drafting of patent claims?

  • The guidance emphasizes integrating judicial exceptions into practical applications and demonstrating real-world benefits. This principle can be applied broadly to ensure patent eligibility, regardless of the technology involved[4].

Q: Why is stakeholder input important in patent policy and enforcement?

  • Stakeholder input ensures that all perspectives are considered, leading to more balanced and effective patent policies. This includes studies on small claims patent courts and other initiatives that impact how patents are enforced and litigated[2].

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. U.S. Patent Small Claims Court - Administrative Conference of the United States.
  3. Patent Claims and Patent Scope - SSRN, September 29, 2016.
  4. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz, July 25, 2024.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,381,724

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,381,724

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France91 00490Jan 17, 1991

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.